AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
September 21, 2021 12:47 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development...
Metacrine-Logo-R Transparent.png.png
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
September 09, 2021 08:05 ET | Metacrine, Inc.
Exceeded enrollment target of 180 total patientsInterim data from the first 60 patients expected early in the fourth quarter of 2021Topline MET642 trial results from all patients are anticipated in...
Metacrine-Logo-R Transparent.png.png
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
September 08, 2021 08:05 ET | Metacrine, Inc.
Featuring KOL and management discussions on the science of FXR agonists and the Company’s programs in NASH and IBD SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a...
Metacrine-Logo-R Transparent.png.png
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:05 ET | Metacrine, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine-Logo-R Transparent.png.png
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
August 12, 2021 08:05 ET | Metacrine, Inc.
Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021Topline results from a Phase 2a trial of MET409 in combination with empagliflozin...
Vitality New.png
FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prodrug
August 10, 2021 09:00 ET | Vitality Biopharma, Inc
CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic...
Metacrine-Logo-R Transparent.png.png
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
August 09, 2021 08:05 ET | Metacrine, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Qu Biologics.png
Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress
July 13, 2021 08:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Metacrine-Logo-R Transparent.png.png
Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress 
July 06, 2021 08:05 ET | Metacrine, Inc.
SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine-Logo-R Transparent.png.png
Metacrine to Present at 2021 Jefferies Healthcare Conference
May 26, 2021 08:05 ET | Metacrine, Inc.
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...